122 related articles for article (PubMed ID: 25957660)
1. 2'-Hydroxyflavanone: A promising molecule for kidney cancer prevention.
Singhal SS; Singhal J; Figarola JL; Riggs A; Horne D; Awasthi S
Biochem Pharmacol; 2015 Aug; 96(3):151-8. PubMed ID: 25957660
[TBL] [Abstract][Full Text] [Related]
2. 2'-hydroxyflavanone inhibits proliferation, tumor vascularization and promotes normal differentiation in VHL-mutant renal cell carcinoma.
Nagaprashantha LD; Vatsyayan R; Singhal J; Lelsani P; Prokai L; Awasthi S; Singhal SS
Carcinogenesis; 2011 Apr; 32(4):568-75. PubMed ID: 21304051
[TBL] [Abstract][Full Text] [Related]
3. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
[TBL] [Abstract][Full Text] [Related]
4. [Prevention of renal carcinoma: the nutri-genetic approach].
Junien C; Dupret JM; Gallou C; Longuemaux S; Richard S; Saquet C; Krishnamoorty R; Delomenie C; Droz D; Bouvier R; Chauveau D; Joly D; Grunfeld JP; Chretien Y; Mejean A; Beroud C
J Soc Biol; 2000; 194(1):29-38. PubMed ID: 11107547
[TBL] [Abstract][Full Text] [Related]
5. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV
Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867
[TBL] [Abstract][Full Text] [Related]
6. Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.
Trotta AM; Santagata S; Zanotta S; D'Alterio C; Napolitano M; Rea G; Camerlingo R; Esposito F; Lamantia E; Anniciello A; Botti G; Longo N; Botti G; Pignata S; Perdonà S; Scala S
J Exp Clin Cancer Res; 2018 Dec; 37(1):297. PubMed ID: 30514329
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
[TBL] [Abstract][Full Text] [Related]
8. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
[TBL] [Abstract][Full Text] [Related]
10. High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma.
Wolff NC; Pavía-Jiménez A; Tcheuyap VT; Alexander S; Vishwanath M; Christie A; Xie XJ; Williams NS; Kapur P; Posner B; McKay RM; Brugarolas J
Oncotarget; 2015 Jul; 6(19):16951-62. PubMed ID: 26219258
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of nuclear factor kappa B in renal cell carcinoma.
Morais C; Gobe G; Johnson DW; Healy H
Int J Biochem Cell Biol; 2011 Nov; 43(11):1537-49. PubMed ID: 21854869
[TBL] [Abstract][Full Text] [Related]
12. The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells.
Peruzzi B; Athauda G; Bottaro DP
Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14531-6. PubMed ID: 16983094
[TBL] [Abstract][Full Text] [Related]
13. Regulation of E2F1 by the von Hippel-Lindau tumour suppressor protein predicts survival in renal cell cancer patients.
Mans DA; Vermaat JS; Weijts BG; van Rooijen E; van Reeuwijk J; Boldt K; Daenen LG; van der Groep P; Rowland BD; Jans JJ; Roepman R; Voest EE; van Diest PJ; Verhaar MC; de Bruin A; Giles RH
J Pathol; 2013 Sep; 231(1):117-29. PubMed ID: 23744542
[TBL] [Abstract][Full Text] [Related]
14. Unique molecular alteration patterns in von Hippel-Lindau (VHL) gene in a cohort of sporadic renal cell carcinoma patients from Pakistan.
Khaliq S; Ajaz S; Firasat S; Shahid S; Hasan AS; Sultan G; Mohsin R; Hashmi A; Mubarak M; Naqvi SA; Rizvi SA; Mehdi SQ; Abid A
Mutat Res; 2014; 763-764():45-52. PubMed ID: 24727139
[TBL] [Abstract][Full Text] [Related]
15. Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism.
Leisz S; Schulz K; Erb S; Oefner P; Dettmer K; Mougiakakos D; Wang E; Marincola FM; Stehle F; Seliger B
Oncotarget; 2015 May; 6(13):11395-406. PubMed ID: 25890500
[TBL] [Abstract][Full Text] [Related]
16. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
[TBL] [Abstract][Full Text] [Related]
17. Hypertension, antihypertensives and mutations in the Von Hippel-Lindau gene in renal cell carcinoma: results from the Netherlands Cohort Study.
Schouten LJ; van Dijk BA; Oosterwijk E; Hulsbergen-van de Kaa CA; Kiemeney LA; Goldbohm RA; Schalken JA; van den Brandt PA
J Hypertens; 2005 Nov; 23(11):1997-2004. PubMed ID: 16208141
[TBL] [Abstract][Full Text] [Related]
18. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer.
Smith K; Gunaratnam L; Morley M; Franovic A; Mekhail K; Lee S
Cancer Res; 2005 Jun; 65(12):5221-30. PubMed ID: 15958567
[TBL] [Abstract][Full Text] [Related]
19. Somatic mutations of the von Hippel-Lindau disease gene in renal carcinomas occurring in patients with long-term dialysis.
Inoue H; Nonomura N; Kojima Y; Shiba M; Oka D; Arai Y; Nakayama M; Takayama H; Nishimura K; Mori H; Okuyama A
Nephrol Dial Transplant; 2007 Jul; 22(7):2052-5. PubMed ID: 17438007
[TBL] [Abstract][Full Text] [Related]
20. Dominant-negative HIF-3 alpha 4 suppresses VHL-null renal cell carcinoma progression.
Maynard MA; Evans AJ; Shi W; Kim WY; Liu FF; Ohh M
Cell Cycle; 2007 Nov; 6(22):2810-6. PubMed ID: 17998805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
